Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BELITE BIO, LLC currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is overseen by 1 distinct examiner, NILOOFAR RAHMANI, in 1 distinct art unit. NILOOFAR RAHMANI is the busiest examiner, with 1 busiest examiner pending action. This 1 pending office action is the only current matter under review for the company.
Because there is only 1 pending office action, the entire current strategy for the Biotechnology & Pharmaceuticals area rests with NILOOFAR RAHMANI. This 1 distinct examiner and 1 distinct art unit combination means that the applicant does not have to navigate multiple examination styles or conflicting art unit policies. Practitioners should focus on the specific prosecution history of NILOOFAR RAHMANI, as this busiest examiner handles the only busiest examiner pending action in the portfolio. The 1:1 ratio between the pending office action and the distinct examiner ensures that all current efforts are directed toward a single point of contact within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562768 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | RAHMANI, NILOOFAR | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562768 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | 30d overdue | Pending | Nov 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial